Search PubMed⌕ Search

Biomedical subjects

M Barry

Publications and source records attributed to M Barry.

At least 217 records · Page 12Linked to original sources
PubMed1974

Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress.

A prospective trial of continuous chelation therapy in children with homozygous thalassaemia on a high transfusion regimen was started in April 1966. The effect of treatment on iron concentration in the liver and on hepatic histology was examined in 49 biopsy specimens obtained from nine chelator-treated patients and nine control patients between April 1966 and April 1973.Chelation therapy was associated with a significant reduction in liver iron concentration, and by the end of the trial the values for the two groups showed no overlap. A similar difference was seen in the amount of hepatic fibrosis, which showed little or no change in the chelator-treated patients but was progressive in the controls.No major clinical differences were seen, probably because both groups included several older children who were heavily loaded with iron at the start of the trial. Among the younger patients, however, puberty was delayed in four of five controls but in only one of four chelator-treated children. Prepubertal growth rate was significantly greater in the chelator-treated patients than in the controls.

Biopsy↗
PubMed1974

Iron and the liver.

Explore the source record for details and available documents.

Alcohol Drinking↗
PubMed1970

Quantitative measurement of iron stores with diethylenetriamine penta-acetic acid.

The use of the chelating agent diethylenetriamine penta-acetic acid (DTPA) for measuring body storage iron was investigated in patients with iron excess whose stores could be determined by venesection. Iron excretion after DTPA bore a close semi-logarithmic relationship to body iron stores when these were increased. The excretion of DTPA-bound (59)Fe was similarly related to the size of the stores, indicating that the increased iron excretion produced by DTPA in iron overload states reflects both increased tissue iron available for chelation and greater stability of the iron-chelate complex. Evidence was obtained that injected (59)Fe-DTPA could be used as a marker for chelated tissue iron enabling the DTPA-chelatable body iron pool to be calculated. There was a highly significant correlation between DTPA-chelatable iron and body storage iron. The regression intercept approximated to the origin, implying a specific relation between the DTPA effect and storage iron. The SE of the mean estimate for storage iron on DTPA-chelatable iron was 0.25 g (5.6%). Mean storage iron values of 392 mg for males and 243 mg for females were predicted from the findings in control subjects.

Adult↗
PubMed1970

Measurement of iron stores in cirrhosis using diethylenetriamine penta-acetic acid.

The chelating agent diethylenetriamine penta-acetic acid was used to measure iron stores in 83 patients with chronic liver disease. Iron chelation was normal in patients with chronic cholestasis. Chelation was increased above the control range in 14 out of 26 patients with alcoholic cirrhosis, in nine out of 28 patients with non-alcoholic cirrhosis, and in 11 out of 15 cirrhotics with a portacaval anastomosis. Iron stores in excess of 1.5 g were predicted from the results in 24 subjects; however, in only three were the values in the range found in propositi with untreated idiopathic haemochromatosis. Increased chelation did not correlate with hepatocellular impairment per se but was associated in 18 cases with surgical or large spontaneous portal systemic shunts. Exogenous factors for excess iron were present in three cases with alcoholic cirrhosis and portal systemic collaterals in one, but no special factor apart from alcoholism was apparent in the remainder. The correlation between chelatable iron and stainable liver iron content was not close and was better in haemochromatosis than in other forms of cirrhosis; in some cases considerable siderosis was present with normal or only slightly increased chelation values.

Adult↗
PubMed1969

Differential ferrioxamine test in haemochromatosis and liver diseases.

The effect of desferrioxamine is examined in more than 100 patients with liver disease, including haemochromatosis, using the differential ferrioxamine test. The procedure gives a reasonably accurate estimate of the size of the iron stores, as determined by multiple venesection, in patients with idiopathic haemochromatosis. Since desferrioxamine is not specific for storage iron, unequivocally abnormal results are not obtained unless the iron load exceeds about 2.3 g. In other forms of liver disease the effect of desferrioxamine is generally increased compared with that in controls. The results show no correlation with the serum iron level or the degree of hepatic siderosis. High values are usual in the presence of jaundice and overlap the range found in untreated haemochromatosis, adding to other evidence that desferrioxamine can derive iron from a hyperchelatable source unrelated to the stores. It is concluded that in liver diseases other than haemochromatosis the results of the test do not reliably reflect body storage iron content.

Adult↗